A Phase 1/2 Study of Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Patients With Progressive Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Biomira USA
- 27 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2018.
- 27 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 08 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov record.